AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20153570 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of ghrelin
Number of subjects: 23
Study 18999067 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated information extraction techniques
Number of subjects: 88
Study 18999067 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage architecture combining a text classifier with a weak regular expression matcher
Number of subjects: 88
Study 15830967 — intervention group
Group type: EXPERIMENTAL
Intervention: End range passive flexion movements (2 series of 10 repetitions)
Number of subjects: 55
Study 15830967 — intervention group
Group type: EXPERIMENTAL
Intervention: End range passive extension movements (2 series of 10 repetitions)
Number of subjects: 55
Study 15830967 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 55
Study 11954880 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (up to 3g daily)
Number of subjects: 4291
Study 11954880 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (up to 3g daily)
Number of subjects: 4291
Study 11954880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (up to 1.2g daily)
Number of subjects: 4291
Study 10980841 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 70000
Study 10980841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 70000
Study 10980841 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 70000
Study 7751888 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic XRT with cisplatin 70 mg/m2 every 3 weeks for three cycles
Number of subjects: 240
Study 7751888 — intervention group
Group type: COMPARATOR
Intervention: Thoracic XRT alone, 60 to 65 Gy total tumor dose in daily fractions of 1.80 to 2.00 Gy
Number of subjects: 240
Study 2113611 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg) daily on days 4 through 17
Number of subjects: 429
Study 2113611 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg) (groups 3 and 4 combined)
Number of subjects: 429
Study 2113611 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate (400 mg) (in subgroup with lowest spinal bone mineral density)
Number of subjects: 429
Study 2113611 — intervention group
Group type: COMPARATOR
Intervention: Phosphate (1.0 g) twice daily on days 1 through 3
Number of subjects: 429
Study 2113611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 1104247 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteolytic enzyme mouthwash consisting mainly of neutral and alkaline proteases and amylase
Number of subjects: 131
Study 1104247 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 131
Study 1104247 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteolytic enzyme mouthwash
Number of subjects: 131
Study 31973645 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care services provided by a multiprofessional team in the hospital, villages, and homes; short-acting morphine oral solution as the only available strong opioid.
Number of subjects: 101
Study 31973645 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care services in rural settings with advanced planning and budgeting.
Number of subjects: 101
Study 31083190 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendoscopic treatment guided by body surface projection
Number of subjects: 69
Study 31083190 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 69
Study 28112771 — intervention group
Group type: EXPERIMENTAL
Intervention: Katz‐ADL index score
Number of subjects: 3184
Study 28112771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lawton IADL scale
Number of subjects: 3184
Study 28112771 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum Detectable Change (MDC)
Number of subjects: 3184
Study 25988553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil-enriched dairy drink (400 mL/day)
Number of subjects: 110
Study 25988553 — intervention group
Group type: COMPARATOR
Intervention: Control dairy drink (400 mL/day)
Number of subjects: 110
Study 24156205 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive toothpaste (5% potassium nitrate and 1,000 ppm fluoride)
Number of subjects: 100
Study 24156205 — intervention group
Group type: COMPARATOR
Intervention: Colgate Cibaca toothpaste (1,000 ppm fluoride; Negative control)
Number of subjects: 100
Study 21700966 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition supplemented with ω‐3 and ω‐6 fatty acids (Omegaven, 0.2 g/kg/d; Lipovenoes 10%, 0.6 g/kg/d)
Number of subjects: 26
Study 21700966 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition with ω‐6 fatty acid (Lipovenoes 10%, 0.8 g/kg/d)
Number of subjects: 26
Study 19371322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1500 mg tomopenem
Number of subjects: 42
Study 16513616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-phase whole-body CT scan (90 mL at 1.8 mL/min; delay, 90 s) during normal expiration (protocol B)
Number of subjects: 60
Study 16513616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-phase whole-body CT scan (90 mL at 1.8 mL/min; delay, 90 s) during shallow breathing (protocol A)
Number of subjects: 60
Study 16513616 — intervention group
Group type: COMPARATOR
Intervention: Multiphase CT scans during shallow breathing (protocol C)
Number of subjects: 60
Study 16513616 — intervention group
Group type: COMPARATOR
Intervention: Multiphase CT scans during normal expiration (protocol D)
Number of subjects: 60
Study 16513616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-phase whole-body CT scan during normal expiration (protocol B) and multiphase CT scan during normal expiration (protocol D)
Number of subjects: 60
Study 12620440 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone 4 mg b.i.d. with placebo (Group I)
Number of subjects: 25
Study 12620440 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg b.i.d. with clomiphene citrate (Group II)
Number of subjects: 25
Study 12620440 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (Group I)
Number of subjects: 25
Study 12620440 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone with clomiphene citrate (Group II)
Number of subjects: 25
Study 12620440 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone (overall effect)
Number of subjects: 25
Study 10854639 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine monotherapy (225 mg, once or twice daily for 6 weeks)
Number of subjects: 15
Study 9093725 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus best supportive care
Number of subjects: 61
Study 9093725 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 61
Study 8097400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 75 mg
Number of subjects: 27
Study 8097400 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 27
Study 3548684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 35
Study 3548684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 30211989 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dental gel containing 2.6% edathamil
Number of subjects: 10
Study 30211989 — intervention group
Group type: COMPARATOR
Intervention: Control gel
Number of subjects: 10
Study 27050038 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care for 12 weeks
Number of subjects: 60
Study 24912461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 142
Study 24912461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Defusion (CD)
Number of subjects: 142
Study 24912461 — intervention group
Group type: COMPARATOR
Intervention: Control intervention focusing on participants' negative thoughts
Number of subjects: 142
Study 22145709 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-standing HEPA filter placed in the child's sleeping area
Number of subjects: 126
Study 22145709 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-standing HEPA filter and window-mounted AC
Number of subjects: 126
Study 22145709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study 19725842 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I BAV
Number of subjects: 89
Study 19725842 — intervention group
Group type: COMPARATOR
Intervention: Type II BAV
Number of subjects: 89
Study 18414647 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg albendazole administered every 6 months for 2 years (5 rounds)
Number of subjects: 3935
Study 18414647 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A administered every 6 months
Number of subjects: 3935
Study 18414647 — intervention group
Group type: COMPARATOR
Intervention: Control group (no albendazole treatment)
Number of subjects: 3935
Study 16012502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable tacks
Number of subjects: 8
Study 16012502 — intervention group
Group type: COMPARATOR
Intervention: Transosseous sutures
Number of subjects: 8
Study 11868059 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin 50 mg administered by mouth 2 times daily for 3 months
Number of subjects: 50
Study 11868059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9878944 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasosartan 50 mg, increased to 100 mg and then to 200 mg if SiDBP > 90 mm Hg
Number of subjects: 262
Study 9878944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 7495780 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alfa therapy (3 MU every day for 3 months)
Number of subjects: 25
Study 7495780 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alfa therapy (3 MU every other day for 3 months)
Number of subjects: 25
Study 7495780 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alfa therapy (3 MU every other day for 6 months)
Number of subjects: 25
Study 7495780 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alfa therapy
Number of subjects: 25
Study 1902264 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural (ED) fentanyl
Number of subjects: 32
Study 1902264 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous (IV) fentanyl
Number of subjects: 32
Study 7325630 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 250 mg twice daily for 4 weeks
Number of subjects: 26
Study 7325630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin 250 mg twice daily for 4 weeks
Number of subjects: 26
Study 7325630 — intervention group
Group type: COMPARATOR
Intervention: Both Amoxicillin and Ampicillin
Number of subjects: 26
Study 7325630 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin and Ampicillin
Number of subjects: 26
Study 30964385 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP video
Number of subjects: 92
Study 30964385 — intervention group
Group type: COMPARATOR
Intervention: Informational video about the hospital's surgical program
Number of subjects: 92
Study 28556876 — intervention group
Group type: EXPERIMENTAL
Intervention: CogniPlus (computer-based cognitive training)
Number of subjects: 60
Study 28556876 — intervention group
Group type: COMPARATOR
Intervention: Classical group-based cognitive training
Number of subjects: 60
Study 25998198 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemodialysis
Number of subjects: 20
Study 25998198 — intervention group
Group type: COMPARATOR
Intervention: Online haemodiafiltration
Number of subjects: 20
Study 23906374 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 1, 5, 10, 25, or 50 mg QD
Number of subjects: 495
Study 23906374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 23906374 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 5 to 50 mg QD
Number of subjects: 495
Study 23906374 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 495
Study 21817188 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug conservation (DC; interrupt ART until CD4(+) T-cell count <250)
Number of subjects: 675
Study 21817188 — intervention group
Group type: COMPARATOR
Intervention: Viral suppression (VS; continued use of ART)
Number of subjects: 675
Study 19655439 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy
Number of subjects: 125
Study 19655439 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy (complete response)
Number of subjects: 125
Study 19655439 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (control group)
Number of subjects: 125
Study 19655439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal-negative carcinomas
Number of subjects: 125
Study 15780528 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen replacement therapy (TERT) - 100 microg 17beta‐estradiol (Climara forte TTS) once a week for 3 months
Number of subjects: 43
Study 15780528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 11900782 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (target peak BAC of 0.05 g/dl)
Number of subjects: 20
Study 11900782 — intervention group
Group type: COMPARATOR
Intervention: Placebo-alcohol
Number of subjects: 20
Study 11900782 — intervention group
Group type: COMPARATOR
Intervention: Soda (diet Sprite)
Number of subjects: 20
Study 10527965 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU recombinant follicle stimulating hormone (recFSH, Puregon)
Number of subjects: 165
Study 10527965 — intervention group
Group type: COMPARATOR
Intervention: 225 IU highly purified urinary follicle stimulating hormone (uFSH-HP, Metrodin-HP)
Number of subjects: 165
Study 7859944 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin concentration increased to 416 +/- 22 pmol/l (step I), 1,170 +/- 79 pmol/l (step II), and 15,936 +/- 1,126 pmol/l (step III) in control subjects; LBF increased from 287 +/- 23 ml.min-1.leg-1 (basal) to 308 +/- 31 ml.min-1.leg-1 (I), 371 +/- 29 ml.min-1.leg-1 (II), and 434 +/- 32 ml.min-1.leg-1 (III).
Number of subjects: 15
Study 7859944 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin concentration increased to 509 +/- 43 pmol/l (step I), 1,299 +/- 122 pmol/l (step II), and 16,524 +/- 1,916 pmol/l (step III) in NIDDM subjects; LBF increased from 302 +/- 12 ml.min-1.leg-1 (basal) to 362 +/- 9 ml.min-1.leg-1 (I), 409 +/- 17 ml.min-1.leg-1 (II), and 472 +/- 29 ml.min-1.leg-1 (III).
Number of subjects: 15
Study 1954811 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 25
Study 1954811 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 25
Study 1954811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CSII and CIT
Number of subjects: 25
Study 1954811 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 25
Study 6781390 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis ($85.82 per year)
Number of subjects: 0
Study 6781390 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis
Number of subjects: 0
Study 31525702 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored dietary intervention over a 6‐mo period
Number of subjects: 39
Study 31525702 — intervention group
Group type: COMPARATOR
Intervention: Standard care for 6 mo followed by individually tailored dietary intervention for the next 6 mo
Number of subjects: 39
Study 30462259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (FCH)
Number of subjects: 47
Study 30462259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 28411254 — intervention group
Group type: EXPERIMENTAL
Intervention: romiplostim
Number of subjects: 1111
Study 28411254 — intervention group
Group type: COMPARATOR
Intervention: control (placebo or standard of care)
Number of subjects: 1111
Study 26494159 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp
Number of subjects: 136
Study 26494159 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 136
Study 26494159 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 136
Study 24494279 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with herbal acupoint sticking (group A)
Number of subjects: 102
Study 24494279 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture alone (group B)
Number of subjects: 102
Study 21555816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) 200 mg twice daily or 400 mg once daily
Number of subjects: 569
Study 21555816 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily
Number of subjects: 569
Study 21555816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 569
Study 21555816 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (ATZ/r)
Number of subjects: 569
Study 19736634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp dissection with meticulous ligation of lymphatic tissue
Number of subjects: 154
Study 19736634 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation technique
Number of subjects: 154
Study 17113564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone posture
Number of subjects: 15
Study 17113564 — intervention group
Group type: COMPARATOR
Intervention: Stoop posture
Number of subjects: 15
Study 15686176 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian suboccipital mini-craniectomy
Number of subjects: 46
Study 15686176 — intervention group
Group type: COMPARATOR
Intervention: Large suboccipital craniectomy
Number of subjects: 46
Study 12596616 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg (group 1)
Number of subjects: 120
Study 12596616 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg/kg and Atracurium 0.25 mg/kg (group 2)
Number of subjects: 120
Study 12596616 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.1 mg/kg to prime Atracurium 0.42 mg/kg (priming group)
Number of subjects: 120
Study 9640195 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 28
Study 9640195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8583482 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 135
Study 8583482 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 135
Study 8583482 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 135
Study 2698570 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (3 X 60 mg/day)
Number of subjects: 30
Study 2698570 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (3 X 50 mg/day)
Number of subjects: 30
Study 782510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicryl (8-0 monofilament)
Number of subjects: 45
Study 782510 — intervention group
Group type: COMPARATOR
Intervention: Monofilament nylon or virgin silk (control)
Number of subjects: 45
Study 31117957 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD) group
Number of subjects: 33
Study 31117957 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-stage PD (LPD) patients
Number of subjects: 33
Study 31117957 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (HV) group
Number of subjects: 33
Study 29103741 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based program (HBP)
Number of subjects: 0
Study 29103741 — intervention group
Group type: COMPARATOR
Intervention: Outpatient physical therapy (OPT)
Number of subjects: 0
Study 25266246 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cups per day of black tea
Number of subjects: 57
Study 25266246 — intervention group
Group type: COMPARATOR
Intervention: Tea-like placebo (flavonoid-free caffeinated placebo)
Number of subjects: 57
Study 25266246 — intervention group
Group type: COMPARATOR
Intervention: Tea-like placebo
Number of subjects: 57
Study 23241739 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (60 μg/kg/day) i.v. for 3 consecutive days before high-dose Melphalan (HDM)
Number of subjects: 281
Study 23241739 — intervention group
Group type: EXPERIMENTAL
Intervention: Palifermin (60 μg/kg/day) i.v. for 3 consecutive days before and after HDM
Number of subjects: 281
Study 23241739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 21525181 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial plexus blockade
Number of subjects: 0
Study 21525181 — intervention group
Group type: COMPARATOR
Intervention: Non-blocked upper extremity
Number of subjects: 0
Study 18373046 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 267
Study 18373046 — intervention group
Group type: COMPARATOR
Intervention: TVT-O
Number of subjects: 267
Study 16110353 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 16 mg/day
Number of subjects: 30
Study 16110353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12520750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraartery chemotherapy with Taxol 135 mg/m2 and DDP 80 mg/m2
Number of subjects: 57
Study 12520750 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy with Taxol 135 mg/m2 and DDP 80 mg/m2
Number of subjects: 57
Study 9807537 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion-health protection intervention
Number of subjects: 2386
Study 9807537 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2386
Study 7658254 — intervention group
Group type: EXPERIMENTAL
Intervention: Four standardized rest periods each day
Number of subjects: 46
Study 2506751 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose intravenous nitroglycerin
Number of subjects: 154
Study 2506751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 180175 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus type 2
Number of subjects: 17
Study 180175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31833569 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (≤50 mg)
Number of subjects: 100
Study 31833569 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (control ≤16 mg)
Number of subjects: 100